Menu Search
Equities

Torrent Pharmaceuticals Ltd

TORNTPHARM:NSI

Torrent Pharmaceuticals Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)3,167.10
  • Today's Change64.20 / 2.07%
  • Shares traded290.86k
  • 1 Year change+49.17%
  • Beta0.4938
Data delayed at least 15 minutes, as of Nov 22 2024 10:27 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy4
Outperform12
Hold6
Sell4
Strong Sell1

Share price forecast in INR

The 27 analysts offering 12 month price targets for Torrent Pharmaceuticals Ltd have a median target of 3,589.00, with a high estimate of 4,035.00 and a low estimate of 2,362.00. The median estimate represents a 13.32% increase from the last price of 3,167.10.
High27.4%4,035.00
Med13.3%3,589.00
Low-25.4%2,362.00

Dividends in INR

In 2024, Torrent Pharmaceuticals Ltd reported a dividend of 28.00 INR, which represents a 27.27% increase over last year. The 22 analysts covering the company expect dividends of 25.96 INR for the upcoming fiscal year, a decrease of 7.29%.
Div growth (TTM)27.27%
More ▼

Earnings history & estimates in INR

On Oct 25, 2024, Torrent Pharmaceuticals Ltd reported 2nd quarter 2025 earnings of 13.37 per share.
The next earnings announcement is expected on Jan 31, 2025.
Average growth rate+4.27%
Torrent Pharmaceuticals Ltd reported annual 2024 earnings of 48.94 per share on May 24, 2024.
Average growth rate+18.00%
More ▼

Revenue history & estimates in INR

Torrent Pharmaceuticals Limited had 2nd quarter 2025 revenues of 28.89bn. This missed the 29.78bn consensus estimate of the 14 analysts following the company. This was 11.50% above the prior year's 2nd quarter results.
Average growth rate+2.10%
Torrent Pharmaceuticals Limited had revenues for the full year 2024 of 107.28bn. This was 11.52% above the prior year's results.
Average growth rate+7.93%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.